Mettler-Toledo International (NYSE:MTD) and aTyr Pharma (NASDAQ:LIFE) are both computer and technology companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, analyst recommendations and institutional ownership.
Valuation and Earnings
This table compares Mettler-Toledo International and aTyr Pharma's gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Mettler-Toledo International | $3.01 billion | 8.68 | $561.11 million | $22.77 | 49.01 |
aTyr Pharma | $420,000.00 | 105.49 | $-23,600,000.00 | ($7.03) | -0.62 |
Mettler-Toledo International has higher revenue and earnings than aTyr Pharma. aTyr Pharma is trading at a lower price-to-earnings ratio than Mettler-Toledo International, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Mettler-Toledo International and aTyr Pharma's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Mettler-Toledo International | 19.36% | 144.89% | 21.11% |
aTyr Pharma | -202.02% | -52.75% | -38.40% |
Institutional and Insider Ownership
93.2% of Mettler-Toledo International shares are owned by institutional investors. Comparatively, 55.8% of aTyr Pharma shares are owned by institutional investors. 3.2% of Mettler-Toledo International shares are owned by company insiders. Comparatively, 9.4% of aTyr Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Volatility and Risk
Mettler-Toledo International has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Comparatively, aTyr Pharma has a beta of 2.17, meaning that its share price is 117% more volatile than the S&P 500.
Analyst Ratings
This is a summary of recent recommendations for Mettler-Toledo International and aTyr Pharma, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Mettler-Toledo International | 4 | 7 | 1 | 0 | 1.75 |
aTyr Pharma | 0 | 0 | 3 | 0 | 3.00 |
Mettler-Toledo International presently has a consensus price target of $868.0833, suggesting a potential downside of 22.22%. aTyr Pharma has a consensus price target of $12.00, suggesting a potential upside of 175.86%. Given aTyr Pharma's stronger consensus rating and higher probable upside, analysts clearly believe aTyr Pharma is more favorable than Mettler-Toledo International.
Summary
Mettler-Toledo International beats aTyr Pharma on 8 of the 14 factors compared between the two stocks.